Overview

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks. In addition patients will be seen for safety visits at 4 and 12 weeks post treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb